NISHIDA Sachiyo

写真a

Affiliation

School of Medicine, Department of Health Care Administration and Management

Job title

Lecturer
To the head of this page.▲

Affiliation 【 display / non-display 】

  • Sapporo Medical University   Health Care Administration and Management   Assistant Professor  

To the head of this page.▲
 

Papers 【 display / non-display 】

  • Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy.

    Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Masanori Nojima, Ryuta Inoue, Hiroshi Kitamura, Toshiaki Tanaka, Hiroko Asanuma, Noriyuki Sato, Naoya Masumori

    Anticancer research   35 ( 1 ) 413 - 8  2015.01  [International journal]

    Authorship：   Lead author

    　View Summary

    We previously found that prostate cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) express hepatocyte growth factor (HGF) and that the HGF/c-MET proto-oncogene product (c-MET) signal has a role in the maintenance of prostate CSCs/CICs in an autocrine fashion. HGF is, thus, a novel marker for prostate CSCs/CICs. We hypothesized that high expression of HGF might be related to early recurrence of prostate cancer after radical prostatectomy, and the purpose of the present study was to evaluate the relationship between expression of HGF in prostate tissues and biochemical recurrence after radical prostatectomy. One hundred-one patients with prostate cancer who underwent open or laparoscopic radical prostatectomy from November 2008 to October 2011 with an adequate prostate-specific antigen (PSA) follow-up period, were investigated. Immunohistochemical staining of HGF was compared to biochemical recurrence after radical prostatectomy. Patients with tumors exhibiting HGF positivity of 5% or more had a significantly shorter biochemical recurrence-free period than that of patients whose tumor HGF positivity was less than 5% (p=0.001). In multivariate Cox regression, preoperative PSA and HGF positivity were independent predictors of biochemical recurrence following prostatectomy. Our finding suggests a direct link between expression of HGF, a novel prostate marker of CSCs/CICs, and biochemical recurrence after radical prostatectomy in patients with prostate cancer.

    PubMed

  • Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor.

    Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Ryuta Inoue, Hiroshi Kitamura, Toshiaki Tanaka, Akari Takahashi, Hiroko Asanuma, Naoya Masumori, Taiji Tsukamoto, Noriyuki Sato

    Cancer science   104 ( 4 ) 431 - 6  2013.04  [International journal]

    Authorship：   Lead author

    　View Summary

    Prostate cancer cells include a small population of cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) that have roles in initiation and progression of the cancer. Recently, we isolated prostate CSCs/CICs as aldehyde dehydrogenase 1-highh (ALDH1(high) ) cells using the ALDEFLUOR assay; however, the molecular mechanisms of prostate CSCs/CICs are still elusive. Prostate CSCs/CICs were isolated as ALDH1(high) cells using the ALDEFLUOR assay, and the gene expression profiles were analyzed using a cDNA microarray and RT-PCR. We found that prostate CSCs/CICs expressed higher levels of growth factors including hepatocyte growth factor (HGF). Hepatocyte growth factor protein expression was confirmed by enzyme linked immunosorbent assay and Western blotting. On the other hand, c-MET HGF receptor was expressed in both CSCs/CICs and non-CSCs/CICs at similar levels. Hepatocyte growth factor and the supernatant of myofibloblasts derived from the prostate augmented prostasphere formation in vitro, and prostasphere formation was inhibited by an anti-HGF antibody. Furthermore, c-MET gene knockdown by siRNA inhibited the prostasphere-forming ability in vitro and tumor-initiating ability in vivo. Taken together, the results indicate that HGF secreted by prostate CSCs/CICs and prostate myofibroblasts has a role in the maintenance of prostate CSCs/CICs in an autocrine and paracrine fashion.

    DOI PubMed

  • Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay.

    Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Hiroshi Kitamura, Akari Takahashi, Naoya Masumori, Taiji Tsukamoto, Noriyuki Sato

    The Journal of urology   188 ( 1 ) 294 - 9  2012.07  [International journal]

    Authorship：   Lead author

    　View Summary

    PURPOSE: Prostate cancer cells include a small population of cancer stem-like/cancer initiating cells, which have roles in cancer initiation and progression. Recently aldehyde dehydrogenase activity was used to isolate stem cells of various cancer and normal cells. We evaluated the aldehyde dehydrogenase activity of the human prostate cancer cell line 22Rv1 (ATCC®) with the ALDEFLUOR® assay and determined its potency as prostate cancer stem-like/cancer initiating cells. MATERIALS AND METHODS: The human prostate cancer cell line 22Rv1 was labeled with ALDEFLUOR reagent and analyzed by flow cytometry. ALDH1(high) and ALDH1(low) cells were isolated and tumorigenicity was evaluated by xenograft transplantation into NOD/SCID mice. Tumor sphere forming ability was evaluated by culturing in a floating condition. Invasion capability was evaluated by the Matrigel™ invasion assay. Gene expression profiling was assessed by microarrays and reverse transcriptase-polymerase chain reaction. RESULTS: ALDH1(high) cells were detected in 6.8% of 22Rv1 cells, which showed significantly higher tumorigenicity than ALDH1(low) cells in NOD/SCID mice (p < 0.05). Gene expression profiling revealed higher expression of the stem cell related genes PROM1 and NKX3-1 in ALDH1(high) cells than in ALDH1(low) cells. ALDH1(high) cells also showed higher invasive capability and sphere forming capability than ALDH1(low) cells. CONCLUSIONS: Results indicate that cancer stem-like/cancer initiating cells are enriched in the ALDH1(high) population of the prostate cancer cell line 22Rv1. This approach may provide a breakthrough to further clarify prostate cancer stem-like/cancer initiating cells. To our knowledge this is the first report of cancer stem-like/cancer initiating cells of 22Rv1 using the aldehyde dehydrogenase activity assay.

    DOI PubMed

  • Japanese female urologists' work‐life balance during the COVID‐19 pandemic

    Sachiyo Nishida, Hitomi Sasaki, Yoshiko Maeda, Masayuki Koyama, Katsuhito Miyazawa, Naoya Masumori

    International Journal of Urology    2022.12

    DOI

  • Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma.

    Masahiro Matsuki, Yoshihiko Hirohashi, Munehide Nakatsugawa, Aiko Murai, Terufumi Kubo, Shinichi Hashimoto, Serina Tokita, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Sachiyo Nishida, Toshiaki Tanaka, Hiroshi Kitamura, Naoya Masumori, Toshihiko Torigoe

    Cancer immunology, immunotherapy : CII   71 ( 4 ) 905 - 918  2022.04  [International journal]

    　View Summary

    Immune checkpoint inhibitors (ICIs) are used in cancer immunotherapy to block programmed death-1 and cytotoxic T-lymphocyte antigen 4, but the response rate for ICIs is still low and tumor cell heterogeneity is considered to be responsible for resistance to immunotherapy. Tumor-infiltrating lymphocytes (TILs) have an essential role in the anti-tumor effect of cancer immunotherapy; however, the specificity of TILs in renal cell carcinoma (RCC) is elusive. In this study, we analyzed a 58-year-old case with clear cell RCC (ccRCC) with the tumor showing macroscopic and microscopic heterogeneity. The tumor was composed of low-grade and high-grade ccRCC. A tumor cell line (1226 RCC cells) and TILs were isolated from the high-grade ccRCC lesion, and a TIL clone recognized a novel neoantigen peptide (YVVPGSPCL) encoded by a missense mutation of the tensin 1 (TNS1) gene in a human leukocyte antigen-C*03:03-restricted fashion. The TNS1 gene mutation was not detected in the low-grade ccRCC lesion and the TIL clone did not recognized low-grade ccRCC cells. The missense mutation of TNS1 encoding the S1309Y mutation was found to be related to cell migration by gene over-expression. These findings suggest that macroscopically and microscopically heterogenous tumors might show heterogenous gene mutations and reactivity to TILs.

    DOI PubMed

display all >>

To the head of this page.▲

Misc 【 display / non-display 】

  • 当院におけるRARP200例の治療成績

    柴森 康介, 佐藤 俊介, 吉川 友博, 桧山 佳樹, 松木 雅裕, 西田 幸代, 伊藤 直樹

    泌尿器外科 ( 医学図書出版(株) )  36 ( 5 ) 426 - 426  2023.05

  • 当院におけるRARP200例の治療成績

    柴森 康介, 佐藤 俊介, 吉川 友博, 桧山 佳樹, 松木 雅裕, 西田 幸代, 伊藤 直樹

    泌尿器外科 ( 医学図書出版(株) )  36 ( 5 ) 426 - 426  2023.05

  • JUAの女性座長リスト企画の経緯と真意

    佐々木 ひと美, 西田 幸代, 小林 知子, 山本 泰代, 前田 佳子, 松下 千枝, 高橋 さゆり, 増田 朋子, 松本 富美, 川崎 麻巳, 久米 春喜, 舛森 直哉, 宮澤 克人, 日本泌尿器科学会ダイバーシティ推進委員会・女性座長候補者リスト作成ワーキンググループ

    日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   np3 - np3  2023.04

  • あなたならどうする?～腹腔鏡下摘除術のトラブルシューティング～ 腹腔鏡下手術トラブル "I'm safe is NOT safe"と気づいたら

    西田 幸代, 舛森 直哉

    日本泌尿器内視鏡・ロボティクス学会総会 ( (一社)日本泌尿器内視鏡・ロボティクス学会 )  36回   SY - 1  2022.11

  • ダイバーシティ 女性泌尿器科医の活躍に対する施策

    宮澤 克人, 野口 満, 中川 徹, 西田 幸代, 吉川 武志, 東武 昇平, 増田 朋子

    日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  113 ( Suppl. ) S136 - S139  2022.11

display all >>

To the head of this page.▲

Awards 【 display / non-display 】

  • 令和3年度学術賞

    2022.07   札幌医科大学医師会  

  • 第15回稲田賞症例報告部門

    2022.06   泌尿器科紀要編集部   難治性低カルシウム・低リン血症をきっかけにFGF23高値を指摘された前立腺癌多発骨転移の1例

To the head of this page.▲

Research Projects 【 display / non-display 】

  • 男性比率の高い領域での女性活躍推進：医学生の診療科選択の現状と課題

    基盤研究(B)

    Project Year :

    2023.04
    -
    2028.03
     

    臼井 恵美子, 西田 幸代, 松倉 力也, 中村 さやか, 奥村 綱雄

  • Isolation of prostate cancer stem-like cell and establishment of specific prostate cancer immunotherapy

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2012.04
    -
    2015.03
     

    MASUMORI Naoya, KITAMURA Hiroshi, NISHIDA Sachiyo

    　View Summary

    The purpose of this study was to investigate prostate Cancer Stem Cells/ Cancer Initiating Cell (CSCs/CICs). Prostate CSCs ／ CICs were isolated as ALDH1 high cells using the ALDH1 activity assay. We found that prostate CSCs ／ CICs expressed higher levels of growth factors including hepatocyte growth factor (HGF). The results indicate that HGF secreted by prostate CSCs ／ CICs. The purpose of the next study was to evaluate the relationship between expression of HGF in prostate tissues and biochemical recurrence after radical prostatectomy. Immunohistochemical staining of HGF was compared to biochemical recurrence after radical prostatectomy. Patients with tumors exhibiting HGF positivity of 5% or more had a significantly shorter biochemical recurrence-free period than that of patients whose tumor HGF positivity was less than 5%. Our data suggests that therapeutic targeting of CSCs/CICs in prostate cancer is a future possibility

To the head of this page.▲
 

Committee Memberships 【 display / non-display 】

  • 2024.02
    -
    Now

      がん診療ガイドライン評価委員会

  • 2023.04
    -
    Now

      広報委員会

  • 2023.04
    -
    Now

      会則検討委員会

  • 2022.11
    -
    Now

      日本泌尿器内視鏡・ロボティクス学会 教育委員会委員

  • 2022.11
    -
    Now

      日本排尿機能学会ダイバーシティ推進委員会委員

display all >>

To the head of this page.▲